CN107184718A - 一种治疗冠心病和心肌梗塞的中药组合物 - Google Patents
一种治疗冠心病和心肌梗塞的中药组合物 Download PDFInfo
- Publication number
- CN107184718A CN107184718A CN201710334305.XA CN201710334305A CN107184718A CN 107184718 A CN107184718 A CN 107184718A CN 201710334305 A CN201710334305 A CN 201710334305A CN 107184718 A CN107184718 A CN 107184718A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- heart disease
- coronary heart
- medicine composition
- miocardial infarction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003814 drug Substances 0.000 title claims abstract description 44
- 239000000203 mixture Substances 0.000 title claims abstract description 21
- 208000029078 coronary artery disease Diseases 0.000 title claims abstract description 19
- 206010061216 Infarction Diseases 0.000 title claims abstract description 18
- 230000007574 infarction Effects 0.000 title claims abstract description 18
- 241000131329 Carabidae Species 0.000 claims abstract description 14
- 240000005001 Paeonia suffruticosa Species 0.000 claims abstract description 14
- 235000003889 Paeonia suffruticosa Nutrition 0.000 claims abstract description 14
- 244000131316 Panax pseudoginseng Species 0.000 claims abstract description 14
- 235000003181 Panax pseudoginseng Nutrition 0.000 claims abstract description 14
- 235000006040 Prunus persica var persica Nutrition 0.000 claims abstract description 14
- 241000270666 Testudines Species 0.000 claims abstract description 14
- 244000144730 Amygdalus persica Species 0.000 claims abstract description 13
- 239000009636 Huang Qi Substances 0.000 claims abstract description 10
- 240000007164 Salvia officinalis Species 0.000 claims abstract description 10
- 235000005412 red sage Nutrition 0.000 claims abstract description 10
- 239000000843 powder Substances 0.000 claims abstract description 9
- 238000012545 processing Methods 0.000 claims abstract description 7
- 238000009413 insulation Methods 0.000 claims description 19
- 238000002360 preparation method Methods 0.000 claims description 19
- 229920002643 polyglutamic acid Polymers 0.000 claims description 17
- 229920000881 Modified starch Polymers 0.000 claims description 16
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 16
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 16
- 235000019991 rice wine Nutrition 0.000 claims description 16
- 108010020346 Polyglutamic Acid Proteins 0.000 claims description 12
- RQFQJYYMBWVMQG-IXDPLRRUSA-N chitotriose Chemical compound O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)[C@@H](CO)O1 RQFQJYYMBWVMQG-IXDPLRRUSA-N 0.000 claims description 12
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 11
- 238000002156 mixing Methods 0.000 claims description 11
- 238000000227 grinding Methods 0.000 claims description 10
- 239000003595 mist Substances 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 8
- 235000019282 butylated hydroxyanisole Nutrition 0.000 claims description 7
- 239000010495 camellia oil Substances 0.000 claims description 7
- 235000019359 magnesium stearate Nutrition 0.000 claims description 7
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 6
- 235000013734 beta-carotene Nutrition 0.000 claims description 6
- 239000011648 beta-carotene Substances 0.000 claims description 6
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 6
- 229920001661 Chitosan Polymers 0.000 claims description 5
- 230000008859 change Effects 0.000 claims description 5
- 229920001542 oligosaccharide Polymers 0.000 claims description 5
- 150000002482 oligosaccharides Chemical class 0.000 claims description 5
- 239000002245 particle Substances 0.000 claims description 5
- 238000007789 sealing Methods 0.000 claims description 5
- 238000010792 warming Methods 0.000 claims description 5
- 239000004255 Butylated hydroxyanisole Substances 0.000 claims description 4
- 235000019482 Palm oil Nutrition 0.000 claims description 4
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 claims description 4
- 229940043253 butylated hydroxyanisole Drugs 0.000 claims description 4
- 235000014655 lactic acid Nutrition 0.000 claims description 4
- 239000004310 lactic acid Substances 0.000 claims description 4
- 239000002540 palm oil Substances 0.000 claims description 4
- 229920001983 poloxamer Polymers 0.000 claims description 4
- 239000007921 spray Substances 0.000 claims description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 3
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims description 3
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims description 3
- 229960002747 betacarotene Drugs 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 229960003511 macrogol Drugs 0.000 claims description 3
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 3
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims description 3
- 239000002994 raw material Substances 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003292 glue Substances 0.000 claims 1
- 150000002576 ketones Chemical class 0.000 claims 1
- 239000008107 starch Substances 0.000 claims 1
- 235000019698 starch Nutrition 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 13
- 230000001225 therapeutic effect Effects 0.000 abstract description 3
- 229940126678 chinese medicines Drugs 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 239000008280 blood Substances 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 7
- 235000009508 confectionery Nutrition 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 5
- 241000545442 Radix Species 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 235000002020 sage Nutrition 0.000 description 4
- 239000002023 wood Substances 0.000 description 4
- 150000001579 beta-carotenes Chemical class 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- LHGVFZTZFXWLCP-UHFFFAOYSA-N guaiacol Chemical class COC1=CC=CC=C1O LHGVFZTZFXWLCP-UHFFFAOYSA-N 0.000 description 3
- 208000019622 heart disease Diseases 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 230000003143 atherosclerotic effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 238000004904 shortening Methods 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 206010003225 Arteriospasm coronary Diseases 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 208000020446 Cardiac disease Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 201000001068 Prinzmetal angina Diseases 0.000 description 1
- 208000012287 Prolapse Diseases 0.000 description 1
- 240000005809 Prunus persica Species 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 208000009325 Variant Angina Pectoris Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000000146 antalgic effect Effects 0.000 description 1
- 230000001663 anti-spastic effect Effects 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 210000003811 finger Anatomy 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004932 little finger Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/58—Reptiles
- A61K35/586—Turtles; Tortoises, e.g. terrapins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/646—Arachnids, e.g. spiders, scorpions, ticks or mites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/40—Cornaceae (Dogwood family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Alternative & Traditional Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Insects & Arthropods (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明公开了一种治疗冠心病和心肌梗塞的中药组合物,涉及中药组合物技术领域,由如下重量的中药制成:全归15g、赤芍15g、桃仁12g、丹参15g、丹皮15g、熟地20g、三七12g、全虫12g、黄芪15g、鳖甲10g、苏木10g、枣皮15g、地鳖虫8g。本发明所述中药组合物适用于治疗冠心病和心肌梗塞,所有中药经炮制后制粉,患者在服用7天后病情基本稳定,继续服用7‑10天以巩固疗效,并取得显效率93%、有效率96%的治疗效果,随访半年未见复发。
Description
技术领域:
本发明涉及中药组合物技术领域,具体涉及一种治疗冠心病和心肌梗塞的中药组合物。
背景技术:
冠心病,即冠状动脉粥样硬化性心脏病,是冠状动脉血管发生动脉粥样硬化病变而引起血管腔狭窄或阻塞,造成心肌缺血、缺氧或坏死而导致的心脏病。临床主要变现为典型胸痛,疼痛从胸骨后或心前区开始,向上放射至左肩、臂,甚至小指和无名指,休息或含服硝酸甘油可缓解。胸痛放散的部位也可涉及颈部、下颌、牙齿、腹部等。胸痛也可出现在安静状态下或夜间,由冠脉痉挛所致,也称变异型心绞痛。
心肌梗塞,即急性心肌梗死,是冠状动脉急性、持续性缺血缺氧所引起的心肌坏死。临床上多有剧烈而持久的胸骨后疼痛,休息及硝酸酯类药物不能完全缓解,伴有血清心肌酶活性增高及进行性心电图变化,可并发心律失常、休克或心力衰竭,常可危及生命。
冠心病和心肌梗塞属于常见心脏病,并没有特效药可以根治,只能服用药物以防止发作和减少发作次数。这两种病症给病人带来极大痛苦,并给病人家属造成困扰和担忧。而采用西药治疗不仅要承受相当昂贵的费用,还要考虑副作用所带来的身体影响,增加患者顾虑,从而得不到及时或有效治疗。
发明内容:
本发明所要解决的技术问题在于提供一种见效快、副作用小且复发率低的治疗冠心病和心肌梗塞的中药组合物。
本发明所要解决的技术问题采用以下的技术方案来实现:
一种治疗冠心病和心肌梗塞的中药组合物,由如下重量的中药制成:
全归15g、赤芍15g、桃仁12g、丹参15g、丹皮15g、熟地20g、三七12g、全虫12g、黄芪15g、鳖甲10g、苏木10g、枣皮15g、地鳖虫8g;
其制备方法为:将全归、丹参、熟地、三七、全虫、黄芪、枣皮加入黄酒中浸润,待药材吸尽黄酒后用文火炒至深黄色,并将赤芍、桃仁、丹皮、鳖甲、苏木、地鳖虫用文火炒至深黄色,晾凉后粉碎,过100-200目筛;冲水口服,一日三次,每次3g。
一种治疗冠心病和心肌梗塞的中药组合物,由如下重量的中药制成:
全归15g、赤芍15g、桃仁12g、丹参15g、丹皮15g、熟地20g、三七12g、全虫12g、黄芪15g、鳖甲10g、苏木10g、枣皮15g、地鳖虫8g;
其制备方法为:将全归、丹参、熟地、三七、全虫、黄芪、枣皮加入黄酒中浸润,待药材吸尽黄酒后用文火炒至深黄色,并将赤芍、桃仁、丹皮、鳖甲、苏木、地鳖虫用文火炒至深黄色,然后将经炮制后的中药和占中药总重0.5%的促煎剂置于砂锅内,加水没过药面,文火煎煮,煮沸后续煮15min,趁热过滤,即得药液;口服,一日三次,每次150mL。
所述促煎剂由如下重量份数的原料制成:聚维酮/壳寡糖0.3g、预胶化淀粉/多聚谷氨酸0.1g、微晶纤维素0.05g、硬脂酸镁0.02g、茶籽油0.005g、丁基羟基茴香醚0.005g、β-胡萝卜素0.002g,其制备方法为:向微晶纤维素中加入茶籽油和β-胡萝卜素,升温至75-80℃保温研磨10min,再加入硬脂酸镁和丁基羟基茴香醚,继续在75-80℃保温研磨10min,然后自然冷却至室温,并加入聚维酮/壳寡糖和预胶化淀粉/多聚谷氨酸,充分混合均匀,即得促煎剂。
所述聚维酮/壳寡糖的制备方法为:向10g水中加入0.2g壳寡糖和0.01g乳酸,溶解完全后于微波频率2450MHz、输出功率700W下微波处理3min,再加入0.2g聚维酮和0.01g氢化棕榈油,混合均匀后继续微波处理5min,并转入5-10℃环境中静置30min,随后再次微波处理5min,所得混合液送入喷雾干燥机中,干燥所得颗粒经超微粉碎机制成微粉。
所述预胶化淀粉/多聚谷氨酸的制备方法为:先将0.1g预胶化淀粉和0.01g聚乙二醇4000升温至105-110℃保温混合10min,然后加入0.05g多聚谷氨酸和0.005g泊洛沙姆,继续在105-110℃保温混合15min,所得混合物转入0-5℃环境中密封静置1h,最后利用超微粉碎机制成微粉。
促煎剂的使用能加快中药药效成分的浸出速度,增加煎煮后所得汤剂中药效成分的含量,提高中药药效成分的利用率,同时缩短服用汤剂的见效时间,从而缩短患者的服药时间,避免长期服药给患者造成的不变;并且该促煎剂在煎煮过程中是以悬浮物的形式存在,经过滤杯过滤后即可有效除去,残留在药液中的少量促煎剂服用后也不会对患者产生任何毒副作用,经内脏代谢后以代谢物形式排出,使用安全性高。
本发明所用中药药性药效:
全归:味甘、辛,性温,补血活血,保肝,利尿,镇痛抗炎。
赤芍:味苦,性微寒,清热凉血,散瘀止痛。
桃仁:味苦、甘,性平,活血祛瘀,润肠通便,止咳平喘。
丹参:味苦,性微寒,活血祛瘀,通经止痛,清心除烦,凉血消痈。
丹皮:味苦,性寒,清热凉血;活血散瘀。
熟地:味甘,性微温,补血养阴,填精益髓。
三七:味甘、味苦,性温,散瘀止血,消肿定痛。
全虫:味辛,性平,息风镇痉,通络止痛,攻毒散结。
黄芪:味甘,性微温,气虚衰弱,表虚自汗。
鳖甲:味咸,性微寒,滋阴潜阳,退热除蒸,软坚散结。
苏木:味甘、咸,性平,活血祛瘀,消肿定痛。
枣皮:味酸,性微温,补益肝肾,涩精固脱。
地鳖虫:味咸,性寒,破瘀血,续筋骨。
本发明的有益效果是:本发明所述中药组合物适用于治疗冠心病和心肌梗塞,所有中药经炮制后制粉,患者在服用7天后病情基本稳定,继续服用7-10天以巩固疗效,并取得显效率93%、有效率96%的治疗效果,随访半年未见复发;并且利用添加促煎剂的煎煮方法所得药液含有高含量的药效成分,提高患者对药效成分的吸收利用率,增强疗效,缩短见效时间,同时该促煎剂使用安全性高,临床未见副反应。
具体实施方式:
为了使本发明实现的技术手段、创作特征、达成目的与功效易于明白了解,下面结合具体实施例,进一步阐述本发明。
实施例1
将15g全归、15g丹参、20g熟地、12g三七、12g全虫、15g黄芪、15g枣皮加入黄酒中浸润,待药材吸尽黄酒后用文火炒至深黄色,并将15g赤芍、12g桃仁、15g丹皮、10g鳖甲、10g苏木、8g地鳖虫用文火炒至深黄色,晾凉后粉碎,过100-200目筛;冲水口服,一日三次,每次3g。
实施例2
将15g全归、15g丹参、20g熟地、12g三七、12g全虫、15g黄芪、15g枣皮加入黄酒中浸润,待药材吸尽黄酒后用文火炒至深黄色,并将15g赤芍、12g桃仁、15g丹皮、10g鳖甲、10g苏木、8g地鳖虫用文火炒至深黄色,然后将经炮制后的中药和占中药总重0.5%的促煎剂置于砂锅内,加水没过药面,文火煎煮,煮沸后续煮15min,趁热过滤,即得药液;口服,一日三次,每次150mL。
促煎剂的制备:向0.05g微晶纤维素中加入0.005g茶籽油和0.002gβ-胡萝卜素,升温至75-80℃保温研磨10min,再加入0.02g硬脂酸镁和0.005g丁基羟基茴香醚,继续在75-80℃保温研磨10min,然后自然冷却至室温,并加入0.3g聚维酮/壳寡糖和0.1g预胶化淀粉/多聚谷氨酸,充分混合均匀,即得促煎剂。
聚维酮/壳寡糖的制备:向10g水中加入0.2g壳寡糖和0.01g乳酸,溶解完全后于微波频率2450MHz、输出功率700W下微波处理3min,再加入0.2g聚维酮和0.01g氢化棕榈油,混合均匀后继续微波处理5min,并转入5-10℃环境中静置30min,随后再次微波处理5min,所得混合液送入喷雾干燥机中,干燥所得颗粒经超微粉碎机制成微粉。
预胶化淀粉/多聚谷氨酸的制备:先将0.1g预胶化淀粉和0.01g聚乙二醇4000升温至105-110℃保温混合10min,然后加入0.05g多聚谷氨酸和0.005g泊洛沙姆,继续在105-110℃保温混合15min,所得混合物转入0-5℃环境中密封静置1h,最后利用超微粉碎机制成微粉。
对照例1
将15g全归、15g丹参、20g熟地、12g三七、12g全虫、15g黄芪、15g枣皮加入黄酒中浸润,待药材吸尽黄酒后用文火炒至深黄色,并将15g赤芍、12g桃仁、15g丹皮、10g鳖甲、10g苏木、8g地鳖虫用文火炒至深黄色,然后将经炮制后的中药和占中药总重0.5%的促煎剂置于砂锅内,加水没过药面,文火煎煮,煮沸后续煮15min,趁热过滤,即得药液;口服,一日三次,每次150mL。
促煎剂的制备:向0.05g微晶纤维素中加入0.005g茶籽油和0.002gβ-胡萝卜素,升温至75-80℃保温研磨10min,再加入0.02g硬脂酸镁和0.005g丁基羟基茴香醚,继续在75-80℃保温研磨10min,然后自然冷却至室温,并加入0.3g聚维酮/壳寡糖和0.1g预胶化淀粉/多聚谷氨酸,充分混合均匀,即得促煎剂。
聚维酮/壳寡糖的制备:向10g水中加入0.2g壳寡糖和0.01g乳酸,溶解完全后于微波频率2450MHz、输出功率700W下微波处理3min,再加入0.2g聚维酮和0.01g氢化棕榈油,混合均匀后继续微波处理5min,并转入5-10℃环境中静置30min,随后再次微波处理5min,所得混合液送入喷雾干燥机中,干燥所得颗粒经超微粉碎机制成微粉。
预胶化淀粉/多聚谷氨酸的制备:先将0.1g预胶化淀粉升温至105-110℃保温混合10min,然后加入0.05g多聚谷氨酸,继续在105-110℃保温混合15min,所得混合物转入0-5℃环境中密封静置1h,最后利用超微粉碎机制成微粉。
对照例2
将15g全归、15g丹参、20g熟地、12g三七、12g全虫、15g黄芪、15g枣皮加入黄酒中浸润,待药材吸尽黄酒后用文火炒至深黄色,并将15g赤芍、12g桃仁、15g丹皮、10g鳖甲、10g苏木、8g地鳖虫用文火炒至深黄色,然后将经炮制后的中药和占中药总重0.5%的促煎剂置于砂锅内,加水没过药面,文火煎煮,煮沸后续煮15min,趁热过滤,即得药液;口服,一日三次,每次150mL。
促煎剂的制备:向0.05g微晶纤维素中加入0.005g茶籽油和0.002gβ-胡萝卜素,升温至75-80℃保温研磨10min,再加入0.02g硬脂酸镁和0.005g丁基羟基茴香醚,继续在75-80℃保温研磨10min,然后自然冷却至室温,并加入0.3g聚维酮/壳寡糖和0.1g预胶化淀粉/多聚谷氨酸,充分混合均匀,即得促煎剂。
聚维酮/壳寡糖的制备:向10g水中加入0.2g壳寡糖,溶解完全后于微波频率2450MHz、输出功率700W下微波处理3min,再加入0.2g聚维酮,混合均匀后继续微波处理5min,并转入5-10℃环境中静置30min,随后再次微波处理5min,所得混合液送入喷雾干燥机中,干燥所得颗粒经超微粉碎机制成微粉。
预胶化淀粉/多聚谷氨酸的制备:先将0.1g预胶化淀粉和0.01g聚乙二醇4000升温至105-110℃保温混合10min,然后加入0.05g多聚谷氨酸和0.005g泊洛沙姆,继续在105-110℃保温混合15min,所得混合物转入0-5℃环境中密封静置1h,最后利用超微粉碎机制成微粉。
实施例3
(1)动物急性毒性试验
试验对象:小白鼠,体重18-22g,雌雄各半;
试验方法:取小白鼠90只,随机选取10只作为空白组,其余平均分为试验一组、试验二组,每个试验组再平均分为4个小组,每个小组10只,试验组给药前禁食12h,将实施例1、实施例2所制药液分别灌喂试验一组、试验二组小白鼠,每只每次灌喂5ml,24h内分别灌喂1、2、3、4次,具体给药组别和给药时间见表1,灌喂后观察7天;
表1 给药组别和给药时间表
试验结果:试验小白鼠活动正常,无毒性反应,无死亡。
(2)动物长期毒性试验
试验对象:大白鼠,体重120-150g,雌雄各半;
试验方法:取大白鼠70只,选取其中10只作为空白组,其余随机平均分为试验一组、试验二组,每个试验组30只,将实施例1、实施例2所制药液分别灌喂试验一组、试验二组大白鼠,试验组每日分别灌喂两次,每日灌喂50ml,连续灌喂90天,监测体重,于最后一次给药24h后断头处死,测血、尿常规、肝功能、肾功能、取心、肾等内脏,观察组织形态的变化;
试验结果:试验组活动正常,无毒性反应,无死亡,处死后的各项检查与空白组无任何区别。
(3)临床研究
试验对象:400名冠心病患者和400名心肌梗塞患者,随机分为4组,每组包含100名冠心病患者和100名心肌梗塞患者;
试验方法:服用实施例1所制中药粉剂的患者,冲水口服,一日三次,每次3g;服用实施例2、对照例1和对照例2所制中药药液的患者,口服药液,一日三次,每次150mL;
试验结果:治疗效果见表2。
表2 对冠心病和心肌梗塞治疗效果
项目 | 实施例1 | 实施例2 | 对照例1 | 对照例2 |
14天显效率/% | 92 | 95 | 94 | 94 |
14天有效率/% | 96 | 98 | 98 | 97 |
17天显效率/% | 94 | 96 | 96 | 95 |
17天有效率/% | 97 | 99 | 98 | 98 |
(4)典型病例
黄某,男,63岁,冠心病病史5年,发病经抢救后服用本发7天病情基本稳定,继续服用10天,随访1年未见复发。
孙某,女,58岁,心肌梗塞病史3年,发病经抢救后服用本发7天病情完全稳定,继续服用10天,随访1年未见复发。
曲某,男,67岁,心肌梗塞病史5年,发病经抢救后服用本发7天病情基本稳定,继续服用7天,随访半年未见复发。
以上显示和描述了本发明的基本原理和主要特征和本发明的优点。本行业的技术人员应该了解,本发明不受上述实施例的限制,上述实施例和说明书中描述的只是说明本发明的原理,在不脱离本发明精神和范围的前提下,本发明还会有各种变化和改进,这些变化和改进都落入要求保护的本发明范围内。本发明要求保护范围由所附的权利要求书及其等效物界定。
Claims (5)
1.一种治疗冠心病和心肌梗塞的中药组合物,其特征在于,由如下重量的中药制成:
全归15g、赤芍15g、桃仁12g、丹参15g、丹皮15g、熟地20g、三七12g、全虫12g、黄芪15g、鳖甲10g、苏木10g、枣皮15g、地鳖虫8g;
其制备方法为:将全归、丹参、熟地、三七、全虫、黄芪、枣皮加入黄酒中浸润,待药材吸尽黄酒后用文火炒至深黄色,并将赤芍、桃仁、丹皮、鳖甲、苏木、地鳖虫用文火炒至深黄色,晾凉后粉碎,过100-200目筛;冲水口服,一日三次,每次3g。
2.一种治疗冠心病和心肌梗塞的中药组合物,其特征在于,由如下重量的中药制成:
全归15g、赤芍15g、桃仁12g、丹参15g、丹皮15g、熟地20g、三七12g、全虫12g、黄芪15g、鳖甲10g、苏木10g、枣皮15g、地鳖虫8g;
其制备方法为:将全归、丹参、熟地、三七、全虫、黄芪、枣皮加入黄酒中浸润,待药材吸尽黄酒后用文火炒至深黄色,并将赤芍、桃仁、丹皮、鳖甲、苏木、地鳖虫用文火炒至深黄色,然后将经炮制后的中药和占中药总重0.5%的促煎剂置于砂锅内,加水没过药面,文火煎煮,煮沸后续煮15min,趁热过滤,即得药液;口服,一日三次,每次150mL。
3.根据权利要求2所述的治疗冠心病和心肌梗塞的中药组合物,其特征在于,所述促煎剂由如下重量份数的原料制成:聚维酮/壳寡糖0.3g、预胶化淀粉/多聚谷氨酸0.1g、微晶纤维素0.05g、硬脂酸镁0.02g、茶籽油0.005g、丁基羟基茴香醚0.005g、β-胡萝卜素0.002g,其制备方法为:向微晶纤维素中加入茶籽油和β-胡萝卜素,升温至75-80℃保温研磨10min,再加入硬脂酸镁和丁基羟基茴香醚,继续在75-80℃保温研磨10min,然后自然冷却至室温,并加入聚维酮/壳寡糖和预胶化淀粉/多聚谷氨酸,充分混合均匀,即得促煎剂。
4.根据权利要求3所述的治疗冠心病和心肌梗塞的中药组合物,其特征在于,所述聚维酮/壳寡糖的制备方法为:向10g水中加入0.2g壳寡糖和0.01g乳酸,溶解完全后于微波频率2450MHz、输出功率700W下微波处理3min,再加入0.2g聚维酮和0.01g氢化棕榈油,混合均匀后继续微波处理5min,并转入5-10℃环境中静置30min,随后再次微波处理5min,所得混合液送入喷雾干燥机中,干燥所得颗粒经超微粉碎机制成微粉。
5.根据权利要求3所述的治疗冠心病和心肌梗塞的中药组合物,其特征在于,所述预胶化淀粉/多聚谷氨酸的制备方法为:先将0.1g预胶化淀粉和0.01g聚乙二醇4000升温至105-110℃保温混合10min,然后加入0.05g多聚谷氨酸和0.005g泊洛沙姆,继续在105-110℃保温混合15min,所得混合物转入0-5℃环境中密封静置1h,最后利用超微粉碎机制成微粉。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710334305.XA CN107184718A (zh) | 2017-05-12 | 2017-05-12 | 一种治疗冠心病和心肌梗塞的中药组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710334305.XA CN107184718A (zh) | 2017-05-12 | 2017-05-12 | 一种治疗冠心病和心肌梗塞的中药组合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107184718A true CN107184718A (zh) | 2017-09-22 |
Family
ID=59873196
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710334305.XA Withdrawn CN107184718A (zh) | 2017-05-12 | 2017-05-12 | 一种治疗冠心病和心肌梗塞的中药组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107184718A (zh) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101085064A (zh) * | 2006-06-08 | 2007-12-12 | 天津天士力制药股份有限公司 | 一种含赤芍治疗心血管疾病的组合物及其制剂 |
-
2017
- 2017-05-12 CN CN201710334305.XA patent/CN107184718A/zh not_active Withdrawn
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101085064A (zh) * | 2006-06-08 | 2007-12-12 | 天津天士力制药股份有限公司 | 一种含赤芍治疗心血管疾病的组合物及其制剂 |
Non-Patent Citations (12)
Title |
---|
何东平等: "《木本油料加工技术》", 31 October 2016, 中国轻工业出版社 * |
周德生等: "《常用中药特殊配伍精要》", 31 October 2007, 山西出版集团山西科学技术出版社 * |
朱定华等: "《基层医生临床实用全书》", 31 January 2006, 中医古籍出版社 * |
李向吉: "《常用中药材应用与栽培》", 31 July 2014, 甘肃科学技术出版社 * |
杨卫平等: "《基层医院内科病治疗经验集》", 31 August 2016, 贵州出版集团 贵州科技出版社 * |
梁瑞宁等: "丹地片对绝经后女性血脂及性激素的影响", 《中国中西医结合杂志》 * |
肖国士等: "《中医秘方全书(珍藏本)超值版》", 30 June 2012, 湖南科学出版社 * |
董秀文等: "《当代心脑肾肝胆病医方集成》", 30 September 2003, 中国医药科技出版社 * |
薛文忠等: "《一味中药巧治病续集》", 30 September 2013, 中国中医药出版社 * |
谷国强等: "《冠状动脉造影及介入治疗》", 30 April 2017, 科学技术文献出版社 * |
邵文杰: "《养生抗衰老中药的应用与研究》", 30 September 1993, 河南科学技术出版社 * |
陈冰俊等: "《失笑散》", 31 January 2013, 中国医药科技出版社 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109731059A (zh) | 一种治疗骨折的中药组合物及其制备方法 | |
CN101332246A (zh) | 治疗冠心病和心绞痛的中药制剂 | |
CN107789484A (zh) | 一种治疗月经不调的中药组合物及其制备方法 | |
CN1733242A (zh) | 一种治疗气虚血瘀型胸痹(冠心病)的药物及其制备工艺 | |
CN102430085B (zh) | 一种治疗冠心病的中药 | |
CN107184718A (zh) | 一种治疗冠心病和心肌梗塞的中药组合物 | |
CN102743707B (zh) | 治疗急性腰扭伤药丸 | |
CN102462751A (zh) | 一种治疗心律失常的中药及制备方法 | |
CN104784659A (zh) | 一种治疗高血脂的中药片剂及其制备方法 | |
CN108853340A (zh) | 一种滋养肝肾的中药及其制备方法 | |
CN105816811A (zh) | 一种治疗心绞痛的中药组合物及其制备方法 | |
CN107115513A (zh) | 一种治疗子宫癌后期出血的中药组合物 | |
CN103463575B (zh) | 一种治疗心脾两虚型心律失常的中药及制备方法 | |
CN105412844A (zh) | 一种预防和治疗心律不齐的药物制剂及其用途 | |
CN106237069A (zh) | 一种治疗冠心病的中药配方 | |
CN105878732A (zh) | 一种治疗糖尿病的中药及其制备方法 | |
CN105079394A (zh) | 一种用于治疗心律不齐的药物制剂 | |
CN105250910A (zh) | 一种治疗痛经的植物足浴粉及其制备方法 | |
CN102487979B (zh) | 红景天微粉莲蓉 | |
CN107158190A (zh) | 一种治疗子宫肌瘤伴出血的中药组合物 | |
CN104096112A (zh) | 一种治疗冠心病心绞痛的中药组合物 | |
CN103495139B (zh) | 一种治疗心脏病的中药组合物 | |
CN107184719A (zh) | 一种治疗腰肌劳损和腰椎增生的中药汤剂 | |
CN107137581A (zh) | 一种治疗小儿发热伴哮喘的中药组合物 | |
CN108452074A (zh) | 改善心肌缺血、供血不足的药膳组合物及散汤剂制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20170922 |
|
WW01 | Invention patent application withdrawn after publication |